Heart failure study aims to tailor treatments using biomarkers
NCT ID NCT07647848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will follow 600 adults with chronic or acute heart failure to see how biomarkers and other factors predict individual responses to standard medications. Participants will have assessments at the start and after 1, 3, and 6 months, with follow-up phone calls every 6 months. The goal is to improve personalized treatment strategies for heart failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors personalize heart failure treatments based on individual biomarkers, improving outcomes.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diabetes drug tame chronic heart failure? a Real-World study investigates
- Heart rehab goes hybrid: can a mix of home and clinic sessions boost adherence?
- Are heart failure patients taking their meds? a urine test at the ER aims to find out
- Can common heart drugs stay safe during a crisis? a trial investigates
- Healthy volunteers test two versions of a promising heart failure drug
- Could a heart pill boost exercise capacity in chronic heart failure?